Phathom Pharmaceuticals Inc
$ 8.51
-0.70%
11 Aug - close price
- Market Cap 693,321,000 USD
- Current Price $ 8.51
- High / Low $ 8.82 / 8.46
- Stock P/E N/A
- Book Value -4.30
- EPS -1.25
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -34.89 %
- 52 Week High 18.31
- 52 Week Low 8.21
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Analyst Target Price
$21.90
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-02-26 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 |
| Reported EPS | -0.08 | -0.18 | -0.16 | -0.15 | -0.9 | -1.07 | -1.05 | -1.05 | -1.25 | -1.11 | -1.39 | -0.76 |
| Estimated EPS | -0.15 | -0.3897 | -0.2 | -0.41 | -0.86 | -1.066 | -1.08 | -1.46 | -1.24 | -1.22 | -1.08 | -0.96 |
| Surprise | 0.07 | 0.2097 | 0.04 | 0.26 | -0.04 | -0.004 | 0.03 | 0.41 | -0.01 | 0.11 | -0.31 | 0.2 |
| Surprise Percentage | 46.6667% | 53.8106% | 20% | 63.4146% | -4.6512% | -0.3752% | 2.7778% | 28.0822% | -0.8065% | 9.0164% | -28.7037% | 20.8333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAT
2026-08-11 09:40:46
Hennion & Walsh Asset Management Inc. significantly increased its stake in Phathom Pharmaceuticals (NASDAQ:PHAT) by 124.3% in Q2, now holding 327,278 shares valued at $3.55 million. Other institutional investors like Millennium Management and Invesco have also expanded their positions, with institutional holdings making up 99.01% of the company's stock. Despite some recent price target reductions, analysts maintain a "Moderate Buy" consensus rating with an average target price of $23.43 for Phathom Pharmaceuticals.
2026-08-07 05:41:44
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Phathom Pharmaceuticals, Inc. (PHAT) on behalf of investors. This investigation follows Phathom's announcement of lowered full-year 2026 net revenue guidance, a significant reduction from figures previously reaffirmed by company executives. Investors who purchased Phathom securities and are aware of facts related to this investigation are encouraged to connect with the firm.
2026-08-07 03:10:27
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shareholders after the company lowered its full-year 2026 net revenue guidance. This reduction followed earlier affirmations of higher revenue projections by company executives. Shareholders are encouraged to contact the firm to learn more about the investigation.
2026-08-05 19:41:59
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Phathom Pharmaceuticals, Inc. (PHAT) on behalf of investors. This investigation follows Phathom's announcement of lowered full-year 2026 net revenue guidance, contradicting earlier reaffirmations by company executives. The firm encourages affected investors to contact them for additional information regarding the securities investigation.
2026-08-04 14:10:16
Levi & Korsinsky is investigating potential securities law violations at Phathom Pharmaceuticals (PHAT) after the company issued a revised FY 2026 revenue outlook of $310 million - $325 million, which was below Wall Street expectations of approximately $332 million. This reduction led to a decline in PHAT shares. The firm encourages investors who lost money on PHAT stock to submit their loss information for a free evaluation.
2026-08-04 10:09:00
Levi & Korsinsky has launched an investigation into potential securities law violations by Phathom Pharmaceuticals (PHAT) after the company issued a revised FY 2026 revenue outlook that fell below analyst expectations, causing its shares to decline. The law firm is encouraging investors who lost money on PHAT stock to submit their loss information for a free evaluation. The investigation focuses on whether the company made misleading statements regarding its revenue projections.
